Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk Hospitalization 19% HCQ for COVID-19  Chevalier et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,213 patients in France Lower mortality (p=0.19) and hospitalization (p=0.36), not sig. Chevalier et al., Frontiers in Medicine, Mar 2023 Favors HCQ Favors control

CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

Chevalier et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1152587
Mar 2023  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 1,213 rheumatic disease patients in France, showing lower risk of mortality and severe cases with HCQ use in univariate analysis, without statistical significance.
Study covers colchicine and HCQ.
risk of death, 34.7% lower, RR 0.65, p = 0.19, treatment 7 of 55 (12.7%), control 109 of 535 (20.4%), NNT 13, odds ratio converted to relative risk.
risk of hospitalization, 19.1% lower, RR 0.81, p = 0.36, treatment 15 of 116 (12.9%), control 180 of 1,097 (16.4%), NNT 29, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chevalier et al., 22 Mar 2023, retrospective, France, peer-reviewed, mean age 70.3, 24 authors. Contact:
This PaperHCQAll
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
Kevin Chevalier, Michaël Genin, Thomas Petit Jean, Jerôme Avouac, Rene-Marc Flipo, Sophie Georgin-Lavialle, Soumaya El Mahou, Edouard Pertuiset, Thao Pham, Amelie Servettaz, Hubert Marotte, Fanny Domont, Pascal Chazerain, Mathilde Devaux, Arsene Mekinian, Jérémie Sellam, Bruno Fautrel, Diane Rouzaud, Esther Ebstein, Nathalie Costedoat-Chalumeau, Christophe Richez, Eric Hachulla, Xavier Mariette, Raphaèle Seror
Frontiers in Medicine, doi:10.3389/fmed.2023.1152587
Results: Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe ), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe ]. Conclusion: In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, autoinflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.
Ethics statement This present study was approved by the institutional review board (APHP Scientific and Ethical Committee, authorization no. CSE 20-60_CovAID) from the Scientific and Ethical Committee of the AP-HP and by the CNIL. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Author contributions KC collected the data, analyzed them, and wrote the manuscript. RS, XM, and EH designed the study. MG and TJ performed the statistics and help for the data collection. JA, R-MF, SG-L, SE, EP, TP, AS, HM, FD, PC, MD, AM, JS, BF, DR, EE, NC-C, and CR collected data from the patients. All authors reviewed and corrected the manuscript. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The Supplementary Material for this article can be found online at: 1152587/full#supplementary-material
Aeschlimann, None
Agard, Nassim Ait-Abdallah, None
Albert, Alcais, Jean-Sébastien Allain; Yannick Allanore; Zahir, Amoura, None
Amouzougan, Emma, None
Arbault, Jean, Arlet, Arnaud, Arniaud, None
Arty-Hue, None
Atlan, None
Aubin, None
Audemard, Verger, None
Audoin-Pajot, None
Austin, A comparison of 12 algorithms for matching on the propensity score
Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivar Behav Res, doi:10.1080/00273171.2011.568786
Austin, Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples, Statist Med, doi:10.1002/sim.3697
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharmaceut Statist, doi:10.1002/pst.433
Avouac, Airó, Carlier, Matucci-Cerinic, Allanore, Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab, Ann Rheum Dis
Avouac, Drumez, Hachulla, Seror, Georgin-Lavialle et al., COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study, Lancet Rheumatol
Bach-Bunner, Bacquet-Deschryver, None
Bader-Meunier, None
Balandraud, None
Balblanc, Ballot-Schmit; Stéphane, Bally, None
Banal, Béatrice Banneville, Barbery, Géraldine, None
Basch, None
Baughman, Lower, Geetha, Smith, Egan et al., The COVID-19 pandemic and ANCA-associated vasculitis -reports from the EUVAS meeting and EUVAS education forum, Sarcoid Vasc Diffuse Lung Dis, doi:10.1016/j.autrev.2021.102986
Baumier, Bayer, None
Bayle, None
Beauvais, None
Beinat, Véronique Belin, Belkhir, Belot, None
Beltai, None
Benainous, None
Benammar, None
Bendahmane, None
Benhamou, Benhamou, None
Benmansour, Pascal, None
Bernoux-Manat, None
Berthet, Berthier, None
Berthoud, Berthoux, None
Bertolini, Bigot, None
Bisson-Vaivre, None
Bitoun, Henry, Desjardins, Vauloup-Fellous, Dib et al., Rituximab impairs B cell response but not T Cell response to COVID-19 vaccine in autoimmune diseases, Arthr Rheumatol, doi:10.3389/fmed.2022.997876
Blaison, Gilles Bolla, Olivier Bonidan, None
Bonnet, None
Borie, None
Borocco, None
Bossert, Boudou, Bouhour, Bouiller, None
Bouillet, None
Bouldoires, Thomas Bourree, Boussen, None
Bourguiba, Delplanque, Vinit, Ackermann, Savey et al., Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218707
Bourguiba, Kyheng, Koné-Paut, Rouzaud, Avouac et al., COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI -the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases, RMD Open, doi:10.1136/rmdopen-2021-002063
Boussoualim, Bouvard, Brondino, None
Brito-Zerón, Gracia-Tello, Robles, Alguacil, Bonet et al., Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis, Viruses
Buchlin, None
Cabantous, Cacoub, None
Cadiou, Cantagrel, Didier, None
Cao, Zhang, Wang, Lu, Zhu et al., Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19), doi:10.1101/2020.03.04.20030395
Carbasse, None
Carteni, Castel, Cathebras, Hervé, None
Cascella, Rajnik, Aleem, Dulebohn, Napoli, Features, Evaluation, and Treatment of Coronavirus (COVID-19)
Cayot-Bouillet, None
Celant, Cerf-Payrastre, None
Chaffin, Benjamin Chaigne, None
Chaillous, Champy, Charcot, None
Charles, Charpin, None
Chatelus, None
Chaudier, Pascal Chazerain, None
Chen, Wang, Gilby, Wei, Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients, J Chem Inf Model, doi:10.1136/annrheumdis-2020-218310
Chertok, None
Chevalier, Chevreau, None
Chotard, None
Chu, Lin, Claudepierre, Clavel, None
Clavel-Osorio, None
Clay, Clet, None
Coassy, None
Cohen, Marie-Eve, None
Cohen, None
Collercandy, None
Colombey, Chloé, None
Combe, Céline Comparon; Elodie, Constant, None
Constantin, Pascal Coquerelle, Corli, Corre, None
Costedoat-Chalumeau, None
Couderc, Couret, None
Courvoisier, Fabienne Coury-Lucas, None
Coutarel, None
Coutier, None
Czernichow, Beeker, Rives-Lange, Guerot, Diehl et al., Obesity doubles mortality in patients hospitalized for severe acute respiratory syndrome coronavirus 2 in Paris hospitals, France: a cohort study on 5,795 patients, Obesity, doi:10.1002/oby.23014
Damade, None
Daver-Malaterre, None
De, None
Decrock, None
Delahousse, None
Delattre, None
Deligny, Denarie, None
Denis, Deprouw, Dernis, Deroux, None
Desbarbieux, None
Descamps, None
Desdoits, None
Deslandre, None
Desmurs, Jacques, None
Desplats, Frédérick, None
Devauchelle-Pensec, None
Devaux, Dhote, None
Diaz, Dieude, Dieudonne, None
Digan, Neuraz, Rogier, Baudoin, Garcelon et al., PyMedExt, un couteau suisse pour le traitement des textes médicaux
Diot, None
Direz, Djeddi, Domont, None
Douvier, Drouet, Dubost, Duc, None
Ducornet, Dufauret-Lombard, None
Dumaine, Dumel, None
Dumoulin-Richez, None
Duquesne, Durand, None
Durandin-Truffinet, None
Duret, Durieux-Mehlman, None
Dusser-Benesty, None
Duval, None
Ebbo, None
Ebinger, Achamallah, Ji, Claggett, Sun et al., Pre-existing traits associated with Covid-19 illness severity, PLoS One, doi:10.1371/journal.pone.0236240
Ebstein, None
Economu-Dubosc, None
El, None
Emilie, Euvrard, Evon, None
England, Roul, Yang, Kalil, Michaud et al., Risk of COVID-19 in rheumatoid arthritis: a national veterans affairs matched cohort study in at-risk individuals, Arthritis Rheumatol, doi:10.1002/art.41800
Esposito, Menon, Ghosh, Putman, Fredenburgh et al., Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study, Am J Respir Crit Care Med, doi:10.1164/rccm.202006-2441LE
Eymard-Gibert, None
Fabre, Fagedet, None
Farge, Bancel, None
Farhat, None
Fauconier, Bruno, None
Fechtenbaum, Renaud Felten, Ferreira-Maldent, None
Feng, Li, Yao, Yu, Zhou et al., The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: a multicenter data analysis, medRxiv, doi:10.1101/2020.04.08.20057539
Feurer, Fichet, None
Flaisler, Flipo, None
Florens, None
Foltz, None
Fontanges, None
Foret, Fougerousse, Fouque-Aubert, None
Foutrier-Morello, None
Francois-Pradier, None
Frantzen, Fremond, None
Fritz, Froissart, Fulpin, None
Fuzibet, None
Gaches, None
Gagneux-Lemoussu, None
Gahier, Galland, Gandjbakhch, None
Galimberti, Mcbride, Cronin, Li, Fox et al., Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia, Clin Dermatol, doi:10.1016/j.clindermatol.2020.05.003
Gao, Ding, Dong, Zhang, Azkur et al., Risk factors for severe and critically ill COVID-19 patients: A review, Allergy
Garcelon, Neuraz, Benoit, Salomon, Burgun, Improving a fulltext search engine: the importance of negation detection and family history context to identify cases in a biomedical data warehouse, J Am Med Inform Assoc, doi:10.1093/jamia/ocw144
Gardette, Garnier, None
Garraud, Jean, Garrot, Gastaldi, None
Gaudin, Véronique Gaud-Listrat, None
Gauthier-Prieur, None
Gauzere, Marion, None
Georgescu, None
Georgin-Lavialle, None
Gerard, None
Gerber, None
Gervais, Gibert, Gibert, Gill, Gillard et al., None
Gianfrancesco, Hyrich, Gossec, Strangfeld, Carmona et al., Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30095-3
Glace, Glanowski, Godeau, Gombert, Gonnet-Gracia, None
Goulenok, Goupille, Olivier Gourmelen, Govindaraju-Audouard, None
Grados, Grall-Lerosey, None
Grardel, Grasland, Grateau, Groza, Guggenbuhl, None
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med
Guichard, Guillaud, Guillaume-Czitrom, None
Guillibert, Xavier Guillot, Guilpain, None
Gury, Guyader, Guyot, Hachulla, None
Haberman, Castillo, Chen, Yan, Ramirez et al., COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108346
Hacquard-Bouder, None
Hasseli, Mueller-Ladner, Schmeiser, Hoyer, Krause et al., National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD, RMD Open, doi:10.1136/rmdopen-2020-001332
Havard, Hellier, Pascal Hennequin, Henry, Hentgen, None
Hermet, Hernandez, Hie, Hilliquin, None
Hinschberger, Hittinger-Roux, None
Holubar, None
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
How, Koy, Hua, Hudry, Huguenel et al., None
Huang, Zhang, Chen, Zhang, Wei et al., Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China, J Immunother Cancer, doi:10.1136/jitc-2021-002630
Isnardi, Roberts, Saurit, Petkovic, Báez et al., Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry, Clin Rheumatol, doi:10.1007/s10067-022-06393-8
Jordan, Adab, Cheng, Covid-19: risk factors for severe disease and death, BMJ
Jouvray, Pierre-Antoine Juge, Juillard, None
Jullien, Abdelkrim Kabchou; Ludovic Karkowski; Françoise Karman; Farid Kemiche, Jérémy Keraen, Kieffer, Kone-Paut, None
Koreichi, None
Kos, Balensiefer, Roth, Ahlgrimm, Sester et al., Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies, Br J Haematol, doi:10.1111/bjh.17266
Kostine, Krebs, Sylvain, Alanore, Lacombe et al., None
Kow, Hasan, Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease, Rheumatol Int
Lamer, Vincent Langlois; Sylvain Lanot; Aurélia, Lanteri, None
Larbre, Latourte, Lavigne; Noémie, Gouellec, Le Guen Guegan et al., None
Lebrun, Emmanuel, None
Legoupil, Legrand, Leguy, None
Leguy-Seguin, Leloire, None
Leipe, Wilke, Ebert, Teufel, Reindl, Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab, Semin Arthr Rheum, doi:10.1016/j.semarthrit.2020.06.013
Leroux, Leroy, Leroy-Gouix, None
Leske, None
Leturcq, Amélie Leurs; Céline Leveque-Michaud, None
Limbach, Frédéric Liote, Lohse, Lucas, Mabrut et al., Pierre Lozac
Magnol, Magy-Bertrand, None
Mahevas, None
Maillard, Thibault, Maillot, Malochet-Guinamand, None
Mangon, Mankikian, Marchou-Lopez, None
Margarit, Thierry Marhadour; Alexandre, None
Mariette, Hubert Marotte, Martin, Thierry Martin;, Mathian et al., None
Maury, Mazet-Guillaume, None
Mazouyez, None
Mazyad, Nadia Mehsen-Cetre, None
Mckeigue, Porter, Hollick, Ralston, Mcallister et al., Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland, Scand J Rheumatol, doi:10.1080/03009742.2022.2063376
Mekinian, Melki, Meric, Messer, Michaud, None
Michel, Michel, Michon, Milesi-Lecat, None
Molto, Moly, Olivier Moranne, Morel, Morel et al., None
Montero, Martínez-Barrio, Serrano-Benavente, González, Rivera et al., Coronavirus disease 2019 (COVID-19) in autoimmune and Frontiers in Medicine 13 frontiersin
Nana, Validation of Neutrophil-to-Lymphocyte Ratio Cut-off Value Associated with High In-Hospital Mortality in COVID-19 Patients, J Gerontol A Biol Sci Med Sci, doi:10.2147/IJGM.S326666
Nguyen, Sabine, None
Nielly, Gaétane Nocturne, Nottez, Olivier, Ollagnon, None
Oziol, Pacaud-Vitoux, None
Pablos, Galindo, Carmona, Lledó, Retuerto et al., Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218296
Padern, Pagnier, Paris, Parrot, Pascart et al., None
Paulin, Pavy, Payet, None
Perard, Pereira-Gillion, Pers, Pertuiset, Petit et al., None
Pichon, Pierreisnard, Pizana, Poignant, Poix et al., None
Pugnet, Déborah Puyraimond-Zemmour, None
Quartier-Dit-Maire, None
Quenet, Viviane Queyrel, Raffray, Razanamahery, None, Philippe Remy
Quintrec, Aude, None
Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, WJCC, doi:10.12998/wjcc.v10.i1.1
Renard, None
Rene, Rey, None
Richard-Colmant, None
Richer, Christophe Richez; Elodie Riviere; Etienne Riviere; Sébastien Riviere, Sophie, Rohmer, Roitg, None
Robinson, Morand, Divergent effects of acute versus chronic glucocorticoids in COVID-19, Lancet Rheumatol, doi:10.1016/S2665-9913(21)00005-9
Rolland, Roriz, Rosenberg, None
Rossi, Marino, Formisano, Venturelli, Vicentini et al., Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy, PLoS One, doi:10.1371/journal.pone.0238281
Rossi, None
Roth, Rouidi, Roumier, Mickaël Rousiere; Clémentine Rousselin; Bénédicte Rouviere, Roux et al., None
Rouzaud, None
Rozenberg, Adeline Ruyssen-Witrand, None
Sacco, Sadji, Sailler, Salliot, Salmon, None
Samaille, Samjee, None
Samson, Saraux, Saunier, Savey, None
Santos, Morales, Álvarez, Castro, Robles et al., Determinants of COVID-19 disease severity in patients with underlying rheumatic disease, Clin Rheumatol
Schmidt, Seguier, Sellam, Senbel, Sene, None
Schulze-Koops, Krueger, Vallbracht, Hasseli, Skapenko, Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab, Ann Rheum Dis
Senet, Seror, Servettaz, Seve, None
Sharmeen, Elghawy, Zarlasht, Yao, COVID-19 in rheumatic disease patients on immunosuppressive agents, Semin Arthr Rheum
Shen, Risk, Schiopu, Hayek, Xie et al., Efficacy of COVID-19 vaccines in patients taking immunosuppressants, Ann Rheum Dis
Shi, Zhang, Jiang, Zhang, Hu et al., Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study, Dia Care, doi:10.2337/dc20-0598
Shin, Shin, Moon, Kim, Yang, Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents, Rev Assoc Med Bras, doi:10.1590/1806-9282.20210568
Sicaud, Sivova, Smets, Sobanski, None
Silva, Boyd, Wallwork, Hsu, Fu et al., Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot, Ann Rheum Dis, doi:10.1016/j.reuma.2021.02.009
Sordet, None
Sornay-Rendu, None
Soubrier, Odile Souchaud-Debouverie, None
Sourisseau-Diverres, None
Southern, Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19, Cleve Clin J Med, doi:10.3949/ccjm.87a.ccc026
Sparsa, None
Spielmann, Stavris, Steib, Straus, None
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physicianreported registry, Ann Rheum Dis
Strotz, Szafors, Séverine Taffignon-Clave, None
Talmud, Chloé, None
Tenenbaum, Theillac, Thomachot, Thierry, Tieulie et al., None
Tepasse, Hafezi, Lutz, Kühn, Wilms et al., Persistent COVID-19 pneumonia and failure to develop Anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma, Clin Lymph Myeloma Leukem, doi:10.1016/j.clml.2020.08.017
Tison, None
Tournadre, Toussirot, Trefond, None
Trijau, Sébastien Trouillier; Anne-Priscille Trouvin, Truchetet, Uettwiller, Ulrich et al., Marie
Valls-Bellec, None
Vaquier, Veillard, Veillon, None
Vial, Jean, Viallard, Victor, None
Victor Audren, Gilles, Avouac, None
Vidon, Mathias Vidon, Vigne, Virone, None
Vijenthira, Gong, Betschel, Cheung, Hicks et al., Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases, Ann Rheum Dis, doi:10.1182/bloodadvances.2021004629
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Warzocha, Daniel Wendling;, Werle, Wibaux, None
Wisniewski, Woessner, Xerri-Campano, None
Wolff, Nee, Hickey, Marschollek, Risk factors for Covid-19 severity and fatality: a structured literature review, Infection, doi:10.1007/s15010-020-01509-1
Yildiz, Castanares-Zapatero, Pierman, Pothen, Greef, None
Zarei, Jalli, Iranpour, Sefidbakht, Soltanabadi et al., Differentiation of chest CT findings between influenza pneumonia and COVID-19: interobserver agreement between radiologists, Acad Radiol, doi:10.1016/j.acra.2021.04.010
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop